“…Antiangiogenic agents prolonged both PFS (HR = 0.58, 95% CI 0.52–0.65, P = .000) and OS (HR=0.84, 95% CI 0.76–0.92, P = .000) in recurrent settings but only PFS in primary settings (HR = 0.88, 95% CI 0.79–0.98, P = .020), longer PFS and OS in both platinum-sensitive recurrent patients (HR = 0.56, 95% CI 0.48–0.64, P = .000, PFS; HR = 0.86, 95% CI 0.76–0.98, P = .027, OS) as well as platinum-resistant recurrent cases (HR = 0.54, 95% CI 0.41–0.71, P = .000, PFS; HR = 0.84, 95% CI 0.71–0.98, P = .029, OS). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Treatment exposure (HR = 2.191; 95% CI: 1.533–3.132; p <  0.001), tumor size (HR = 1.973; 95% CI: 1.230–3.164; p = 0.005), serum AFP level (HR = 1.752; 95% CI: 1.277–2.403; p = 0.001), and TNM stage (HR = 0.470; 95% CI: 0.319–2.504; p <  0.001), were independent factors for OS in HCC patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Other potential risk factors included history of extrapyramidal symptoms (HR = 1.35), other movement disorders (parkinsonism, HR = 1.43; bradykinesia, HR = 1.44; tremors, HR = 2.12, and myoclonus, HR = 2.33), and diabetes (HR = 1.13). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…For advanced/metastatic RCC of favourable risk, avelumab plus axitinib was associated with a significantly higher improvement in progression-free survival (PFS) than sunitinib (HR 0.57, 95% CI 0.34 to 0.96). For intermediate-risk patients, cabozantinib, nivolumab plus ipilimumab, pembrolizumab plus axitinib and avelumab plus axitinib were associated with significantly higher improvement in PFS than sunitinib (HR 0.63, 95% CI 0.44 to 0.97; HR 0.66, 95% CI 0.53 to 0.81; HR 0.58, 95% CI 0.44 to 0.80; HR 0.62, 95% CI 0.47 to 0.83, respectively); pembrolizumab plus axitinib and nivolumab plus ipilimumab were associated with significantly higher improvement in overall survival (OS) than sunitinib (HR 0.53, 95% CI 0.34 to 0.81; HR 0.66, 95% CI 0.50 to 0.87, respectively). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND AND AIMS: Evaluations of adverse heart rate (HR)-responses and HR-variations during anaesthesia in beach-chair-position (BCP) for shoulder surgeries have not been done earlier. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…On multivariate analysis, end-stage renal disease(Hazard ratio (H.R.) = 2.33, p = 0.021), m-ALBI grade 2a (H.R. = 2.86, p = 0.003) and m-ALBI grades 2b or 3 (H.R. = 2.30, p = 0.009), APRI greater than 1 (H.R. = 1.92, p = 0.036) and 2(nd) recurrence occurring within 1 year (H.R. = 2.69, p<0.001) were significantly associated with worse survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…High PC3X and AFP predicted for poor PFS (HR(PC3X)=1.80, p=0.032; HR(AFP)=1.70, p=0.031) and OS (HR(PC3X)=2.12, p=0.024; HR(AFP)=2.55; p=0.003), whereas PRO-C3 did not (PFS: HR=1.19, p=0.059 and OS: HR=1.12, p=0.324). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Genetic factors may influence the susceptibility to high-risk (hr) human papillomavirus (HPV) infection and persistence. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: To reach non-participants, reluctant to undergo clinician-based cervical cancer screening and vaginal self-sampling, urine collection for high-risk human papillomavirus detection (hrHPV) may be valuable. Using two hrHPV DNA assays, we evaluated the concordance of hrHPV positivity in urine samples in comparison with vaginal self-samples and cervical cytology samples taken by the general practitioner (GP). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Major non-fatal adverse events were associated with age (HR 1.4, p < 0.022). New episodes of infection were correlated with S aureus infection (HR 4.8, p < 0.001), right-sided endocarditis (HR 7.4, p < 0.001), spondylodiscitis (HR 6.8, p < 0.004) and intravenous drug abuse (HR 10.3, p < 0.001). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The GS HR measurements for the resting pig had a mean value of 161.43 bpm and SD of 10.11 bpm. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study we analyze the TIME comparing high-risk (HR) and low-risk (LR) NBs using multiplex platforms. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: Age ≥ 65 years [Hazard ratio (HR) = 1.509, 95% confidence interval (CI) 1.299–1.754], race (HR = 1.220, 95% CI 1.028–1.448), marital status (unmarried, single or widowed, HR = 1.264, 95% CI 1.098–1.454), tumor grade II (HR = 3.520, 95% CI 2.915–4.250), the American Joint Committee on Cancer (AJCC) stage (T3: HR = 1.597, 95% CI 1.286–1.984; T4: HR = 2.446, 95% CI 1.796–3.331; N1: HR = 1.504, 95% CI 1.176–1.924; M1: HR = 9.875, 95% CI 8.204–11.887) at diagnosis, radiotherapy (HR = 1.892, 95% CI 1.365–2.623), regional nodes positive (HR = 2.498, 95% CI 1.906–3.274) increased risk of PCa-specific mortality for Asian-American PCa patients, while surgical (HR = 0.716, 95% CI 0.586–0.874) reduced the risk. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Differences between Prolif− and Prolif+ were compared by Wilcoxon test in each sub-group HR+ and HR−. Results are expressed as median [25th–75th percentile]. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The CHADS(2) score [hazard ratio (HR) =1.43], hypertension (HR =2.18), age more than 75 (HR =0.49), diabetes (HR =0.57), BLED score (HR=0.28), stroke (HR =19.8), hepatopathy (HR =3.97), nephropathy (HR =2.93), INR instability (HR =4.18), drinking (HR =2.67), and drugs (HR =2.36) were significant risk factors for long-term AE. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Median OS was 19 and 12 months for the S+SRS and SRS groups, respectively [HR 1.73 (1.35-2.22) (P<0.001)]. On UVA, number of BrM [HR 1.13 (1.06-1.22) (P<0.001)], ECOG 3-4 [HR 2.78 (1.73-4.46) (P<0.001)], and extracranial disease (ECD) at BrM treatment [HR 1.82 (1.37,2.40) (P<0.001)], correlated inversely with OS. …”
Enlace del recurso
Enlace del recurso

“…In multivariate analysis, the presence of emphysema (adjusted hazard ratio [aHR]=3.73, P=0.033), severity measured using the visual sum score (mild-to-moderate, aHR=8.58, P=0.016; severe, aHR=3.58, P=0.042), Goddard sum score (mild-to-moderate, aHR=3.31, P=0.058; severe, aHR=5.38, P=0.014), and the upper lobe distribution of emphysema (aHR=3.76, P=0.032) were associated with a higher risk of pneumonia. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Penile Squamous Cell Carcinoma (PSCC) is a rare but aggressive cancer and approximately 30–50% of cases are associated with high risk human papillomavirus (HR-HPV). HR-HPV infection has been shown to correlate with expression of protein p16(INK4a) (p16). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS ≥ 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso